Glucagon for hypoglycaemia treatment in type 1 diabetes
- 25 September 2020
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (5) , e3409
Abstract
To achieve strict glycaemic control and avoid chronic diabetes complications, individuals with type 1 diabetes (T1D) are recommended to follow an intensive insulin regimen. However, the risk and fear of hypoglycaemia often prevent individuals from achieving the treatment goals. Apart from early insulin suspension in insulin pump users, carbohydrate ingestion is the only option for preventing and treating non‐severe hypoglycaemic events. These rescue treatments may give extra calories and cause overweight. As an alternative, the use of low‐dose glucagon to counter hypoglycaemia has been proposed as a tool to raise glucose concentrations without adding extra calories. Previously, the commercially available glucagon formulations required reconstitution from powder to a solution before being injected subcutaneously or intramuscularly—making it practical only for treating severe hypoglycaemia. Several companies have developed more stable formulations that do not require the time‐consuming reconstitution process before use. As well as treating severe hypoglycaemia, non‐severe and impending hypoglycaemia can also be treated with lower doses of glucagon. Once available, low‐dose glucagon can be either delivered manually, as an injection, or automatically, by an infusion pump. This review focuses on the role and perspectives of using glucagon to treat and prevent hypoglycaemia in T1D.Keywords
Funding Information
- Novo Nordisk Foundation Center for Basic Metabolic Research
This publication has 102 references indexed in Scilit:
- Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approachDiabetes, Metabolic Syndrome and Obesity, 2011
- Uncoupling Intensive Insulin Therapy from Weight Gain and Hypoglycemia in Type 1 DiabetesDiabetes Technology & Therapeutics, 2011
- Temporal patterns in overweight and obesity in Type 1 diabetesDiabetic Medicine, 2010
- Barriers to Physical Activity Among Patients With Type 1 DiabetesDiabetes Care, 2008
- Identification of a novel human glucagon receptor promoter: Regulation by cAMP and PGC-1αGene, 2007
- Evidence for a vicious cycle of exercise and hypoglycemia in type 1 diabetes mellitusDiabetes/Metabolism Research and Reviews, 2004
- Adverse Events and Their Association With Treatment Regimens in the Diabetes Control and Complications TrialDiabetes Care, 1995
- The Role of Glucagon, Catecholamines and Cortisol in Counterregulation of Insulin‐induced Hypoglycemia in Normal ManActa Medica Scandinavica, 1986
- The effect of intraportal and peripheral infusions of glucagon on insulin and glucose concentrations and glucose tolerance in normal manDiabetologia, 1977
- The amino acid sequence of human glucagonFEBS Letters, 1972